Prevalence and subtypes of ciprofloxacin-resistant Campylobacter spp. in commercial poultry flocks before, during, and after treatment with fluoroquinolones

被引:78
作者
Humphrey, TJ
Jorgensen, F
Frost, JA
Wadda, H
Domingue, G
Elviss, NC
Griggs, DJ
Piddock, LJV [1 ]
机构
[1] Univ Birmingham, Sch Med, Div Immun & Infect, Antimicrobial Agents Res Grp, Birmingham B15 2TT, W Midlands, England
[2] Avigen Ltd, Broxburn, W Lothian, Scotland
[3] Hlth Protect Agcy, Campylobacter Reference Unit, Specialist & Reference Microbiol Div, London, England
[4] Univ Bristol, Sch Clin Vet Sci, Bristol BS8 1TH, Avon, England
[5] Univ Bristol, Food Microbiol Collaborating Unit, Hlth Protect Agcy SW, Sch Clin Vet Sci, Bristol BS8 1TH, Avon, England
关键词
D O I
10.1128/AAC.49.2.690-698.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Five commercial broiler chicken flocks were treated with either difloxacin or enrofloxacin for a clinically relevant infection, as instructed by a veterinarian. Campylobacters were isolated from individual fecal samples and from samples associated with the broiler environment before, during, and after treatment. Ciprofloxacin-resistant Campylobacter jejuni and/or C. coli strains were detected pretreatment in four flocks, but they constituted a very small proportion of the campylobacters present. When the broilers were treated with a fluoroquinolone, a rapid increase in the proportion of ciprofloxacin-resistant campylobacters was observed. During treatment nearly 100% of campylobacters were resistant, and in some flocks a high proportion of resistant strains persisted for up to 4 weeks after treatment. Prior to treatment a variety of campylobacter subtypes were present. During and after treatment considerable changes in both species and subtype prevalence were observed, but no single fluoroquinolone-resistant clone became dominant. Instead, resistant C. coli strains or a mixture of resistant C. coli and C.jejuni strains became dominant, whereas susceptible C.jejuni strains had usually been dominant prior to treatment. The resistant subtypes which emerged and became dominant were not always the same as those detected pretreatment. The persistence of resistant strains for up to 4 weeks posttreatment has important implications for any strategy designed to avoid the introduction of such strains into the food chain.
引用
收藏
页码:690 / 698
页数:9
相关论文
共 45 条
[1]   Trends in indigenous foodborne disease and deaths, England and Wales: 1992 to 2000 [J].
Adak, GK ;
Long, SM ;
O'Brien, SJ .
GUT, 2002, 51 (06) :832-841
[2]   Antimicrobial resistance in Campylobacter from broilers:: association with production type and antimicrobial use [J].
Avrain, L ;
Humbert, F ;
L'Hospitalier, R ;
Sanders, P ;
Vernozy-Rozand, C ;
Kempf, I .
VETERINARY MICROBIOLOGY, 2003, 96 (03) :267-276
[3]   Broiler carcass contamination with Campylobacter from feces during defeathering [J].
Berrang, ME ;
Buhr, RJ ;
Cason, JA ;
Dickens, JA .
JOURNAL OF FOOD PROTECTION, 2001, 64 (12) :2063-2066
[4]   Applicability of a rapid duplex real-time PCR assay for speciation of Campylobacter jejuni and Campylobacter coli directly from culture plates [J].
Best, EL ;
Powell, EJ ;
Swift, C ;
Grant, KA ;
Frost, JA .
FEMS MICROBIOLOGY LETTERS, 2003, 229 (02) :237-241
[5]  
Bolton F. J., 1992, IDENTIFICATION METHO, P151
[6]   Ciprofloxacin resistance in Campylobacter jejuni:: case-case analysis as a tool for elucidating risks at home and abroad [J].
Charlett, A ;
Cowden, JM ;
Frost, JA ;
Gillespie, IA ;
Millward, J ;
Neal, KR ;
O'Brien, JSJ ;
Painter, MJ ;
Syed, Q ;
Tompkins, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (04) :561-568
[7]  
*COMM DIS SURV CTR, 2002, ANT RES 2000
[8]   QUINOLONE RESISTANCE IN CAMPYLOBACTER ISOLATED FROM MAN AND POULTRY FOLLOWING THE INTRODUCTION OF FLUOROQUINOLONES IN VETERINARY-MEDICINE [J].
ENDTZ, HP ;
RUIJS, GJ ;
VANKLINGEREN, B ;
JANSEN, WH ;
VANDERREYDEN, T ;
MOUTON, RP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 (02) :199-208
[9]   Quinolone and macrolide resistance in Campylobacter jejuni and C-coli:: Resistance mechanisms and trends in human isolates [J].
Engberg, J ;
Aarestrup, FM ;
Taylor, DE ;
Gerner-Smidt, P ;
Nachamkin, I .
EMERGING INFECTIOUS DISEASES, 2001, 7 (01) :24-34
[10]  
*FOOD DRUG ADM, 2002, FED REGISTER, V67, P7700